All-trans retinoic acid suppresses liver injury induced by Propionibacterium acnes and lipopolysaccharide in rats

被引:14
|
作者
Motomura, K [1 ]
Sakai, H [1 ]
Isobe, H [1 ]
Nawata, H [1 ]
机构
[1] Kyushu Univ, Fac Med, Dept Internal Med 3, Fukuoka 81282, Japan
关键词
all-trans retinoic acid; immunomodulator; Kupffer cell; liver injury; LPS; Propionibacterium acnes; superoxide; TNF-alpha;
D O I
10.1111/j.1440-1746.1997.tb00388.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
All-traits retinoic acid (ATRA) has been reported to exert major effects on the immune system, including monocytes/macrophages. The present study was designed to determine whether ATRA would modulate macrophage-associated liver injury induced by Propionibacterium acnes and lipopolysaccharide (LPS) in rats. All-traits retinoic acid administration alleviated the liver injury and reduced the incidence of death following hepatic failure. Serum alanine aminotransferase (ALT) levels 5 h after, and survival rates within 12 h after the administration of LPS were significantly lower in the ATRA-treated group (134 +/- 119 IU/L and 72.7%) compared with the control group (713 +/- 411 IU/L and 18.2%; P < 0.05). Histological findings supported these results. These effects may be due to suppression of tumour necrosis factor-alpha (TNF-alpha) and superoxide anions produced by activated macrophages. Serum levels of TNF-alpha 1 h after LPS administration were significantly lower in the ATRA-treated group (60.5 +/- 7.0 ng/mL) as compared with the control group (105.2 +/- 39.3 ng/mL; P < 0.05). Formazan deposition that was generated by the perfusion of the liver with nitroblue tetrazolium, also suggested suppression of the release of superoxide anions from hepatic macrophages. These results suggest that ATRA acts as an immunomodulator in liver injury by suppressing the activation of liver macrophages.
引用
收藏
页码:887 / 892
页数:6
相关论文
共 50 条
  • [21] All-trans retinoic acid (ATRA) prevents lipopolysaccharide-induced neuroinflammation, amyloidogenesis and memory impairment in aged rats
    Behairi, Nassima
    Belkhelfa, Mourad
    Rafa, Hayet
    Labsi, Moussa
    Deghbar, Nahla
    Bouzid, Nora
    Mesbah-Amroun, Hamida
    Touil-Boukoffa, Chafia
    JOURNAL OF NEUROIMMUNOLOGY, 2016, 300 : 21 - 29
  • [22] ENZYMATIC OXIDATION OF ALL-TRANS RETINAL TO ALL-TRANS RETINOIC ACID
    BHAT, PV
    POISSANT, L
    LACROIX, A
    FEDERATION PROCEEDINGS, 1987, 46 (04) : 1187 - 1187
  • [23] Folic acid rescues all-trans retinoic acid-induced anorectal malformations in rats
    Wu, Fang
    Gu, Chenchao
    Bi, Yang
    Guo, Zhenhua
    Wang, Yi
    BIRTH DEFECTS RESEARCH, 2020, 112 (20): : 1850 - 1856
  • [24] Vasculitis and all-trans retinoic acid
    Fregoni, V
    Pastorini, A
    Camerone, G
    HAEMATOLOGICA, 1996, 81 (05) : 485 - 486
  • [25] All-trans retinoic acid-induced multiple mononeuropathies
    Yamaji, S
    Kanamori, H
    Mishima, A
    Fujisawa, S
    Motomura, S
    Mohri, H
    AMERICAN JOURNAL OF HEMATOLOGY, 1999, 60 (04) : 311 - 311
  • [26] ALL-TRANS RETINOIC ACID-INDUCED CARDIOVASCULAR MALFORMATIONS
    IRIE, K
    ANDO, M
    TAKAO, A
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1990, 588 : 387 - 388
  • [27] A rare case of all-trans retinoic acid induced myocarditis
    Ul Hassan, Imtiaz
    Chowdhary, Amrit
    Kidambi, Ananth
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING, 2021, 22 (08) : E131 - E131
  • [28] Granulomatous tubulointerstitial nephritis induced by all-trans retinoic acid
    Tomita, N
    Kanamori, H
    Fujita, H
    Maruta, A
    Naitoh, A
    Nakamura, S
    Ota, Y
    Nozue, N
    Kihara, M
    Ishigatsubo, Y
    ANTI-CANCER DRUGS, 2001, 12 (08) : 677 - 680
  • [29] All-trans retinoic acid suppresses topoisomerase IIα through the proteasomal pathway
    Li, Xiaoting
    Li, Yuan
    Shen, Xin
    Fu, Shilong
    Han, Suping
    Feng, Qing
    ANTI-CANCER DRUGS, 2015, 26 (07) : 737 - 746
  • [30] Combined treatment of All-trans retinoic acid with Tamoxifen suppresses ovarian cancer
    Xu, Rui
    Yang, Xiaowen
    Tang, Bin
    Mao, Yifan
    Jiang, Feiyun
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 94 (02) : 259 - 270